Colorectal cancer statistics, 2020
2020/03/05 by Rebecca L. Siegel, Kimberly D. Miller, Ann Goding Sauer +6 · 1 voice · 40 citations
Medicine · #Colorectal Cancer Screening and Detection #Colorectal Cancer Surgical Treatments #Gastric Cancer Management and Outcomes
paper · pdf · doi:10.3322/caac.21601
openalex publication_date 2020/03/05 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Abstract
Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC occurrence based on incidence data (available through 2016) from population-based cancer registries and mortality data (through 2017) from the National Center for Health Statistics. In 2020, approximately 147,950 individuals will be diagnosed with CRC and 53,200 will die from the disease, including 17,930 cases and 3,640 deaths in individuals aged younger than 50 years. The incidence rate during 2012 through 2016 ranged from 30 (per 100,000 persons) in Asian/Pacific Islanders to 45.7 in blacks and 89 in Alaska Natives. Rapid declines in incidence among screening-aged individuals during the 2000s continued during 2011 through 2016 in those aged 65 years and older (by 3.3% annually) but reversed in those aged 50 to 64 years, among whom rates increased by 1% annually. Among individuals aged younger than 50 years, the incidence rate increased by approximately 2% annually for tumors in the proximal and distal colon, as well as the rectum, driven by trends in non-Hispanic whites. CRC death rates during 2008 through 2017 declined by 3% annually in individuals aged 65 years and older and by 0.6% annually in individuals aged 50 to 64 years while increasing by 1.3% annually in those aged younger than 50 years. Mortality declines among individuals aged 50 years and older were steepest among blacks, who also had the only decreasing trend among those aged younger than 50 years, and excluded American Indians/Alaska Natives, among whom rates remained stable. Progress against CRC can be accelerated by increasing access to guideline-recommended screening and high-quality treatment, particularly among Alaska Natives, and elucidating causes for rising incidence in young and middle-aged adults.
Citations
Cited by
- Cancer statistics for adolescents and young adults, 2020
- Cancer statistics for African American/Black People 2022
- Cancer statistics for <scp>A</scp> merican <scp>I</scp> ndian and <scp>A</scp> laska <scp>N</scp> ative individuals, 2022: Including increasing disparities in early onset colorectal cancer
- Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN
- Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer
- <i>KRAS</i> and <i>BRAF</i> Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis
- Curcuma as an adjuvant in colorectal cancer treatment
- Colon cancer checks in when bile acids check out: the bile acid–nuclear receptor axis in colon cancer
- Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon
- Mechanism of Sijunzi Decoction in the treatment of colorectal cancer based on network pharmacology and experimental validation
- Colorectal cancer statistics, 2026
- Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy
- Skin Lesion Classification Based on ResNet-50 Enhanced With Adaptive Spatial Feature Fusion
- Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial
- Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis
- HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway. [europepmc]
- An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer. [europepmc]
- Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review). [europepmc]
- Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. [europepmc]
- Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women. [europepmc]
- IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation. [europepmc]
- Circ3823 contributes to growth, metastasis and angiogenesis of colorectal cancer: involvement of miR-30c-5p/TCF7 axis. [europepmc]
- Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy. [europepmc]
- Global colorectal cancer burden in 2020 and projections to 2040. [europepmc]
- Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. [europepmc]
- LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. [europepmc]
- Risk Factors for the Diagnosis of Colorectal Cancer. [europepmc]
- Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts. [europepmc]
- Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis. [europepmc]
- Colorectal liver metastasis: molecular mechanism and interventional therapy. [europepmc]
- Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. [europepmc]
- Fusobacterium nucleatum reduces METTL3-mediated m 6 A modification and contributes to colorectal cancer metastasis. [europepmc]
- Colorectal Cancer-Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD-L1 Expression in Tumor-Associated Macrophages. [europepmc]
- Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites. [europepmc]
- Current and future colorectal cancer screening strategies. [europepmc]
- PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. [europepmc]
- Is early-onset cancer an emerging global epidemic? Current evidence and future implications. [europepmc]
- Young-onset colorectal cancer. [europepmc]
- Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. [europepmc]
- Colorectal Cancer: Epidemiology, Risk Factors, and Prevention. [europepmc]
Discussions
Related